

Jordan R. Smith, PharmD
Assistant Professor, Department of Clinical Sciences
High Point University Fred Wilson School of Pharmacy

Personal:

4423 Saddlewood Club Drive
High Point, NC 27265
(989)-444-0099
jordraph@gmail.com

Business:

802 International Ave.
High Point, NC 27268
(336)-841-9716
jsmith5@highpoint.edu

EDUCATION/TRAINING

Infectious Diseases Pharmacokinetic/Pharmacodynamic Fellowship **2013 - 2015**

Anti-Infective Research Laboratory
Wayne State University
Detroit, MI
Program Director: Michael J. Rybak, PharmD, MPH

ASHP Accredited PGY1 Pharmacy Practice Residency **2012 – 2013**

Moses Cone Hospital
Greensboro, NC
Program Director: Jackie Roh, RPh

Doctor of Pharmacy **2008 – 2012**

University of Michigan College of Pharmacy
Ann Arbor, MI

Bachelor of Science in Biology **2004 – 2008**

University of Michigan
Ann Arbor, MI

LICENSURES/CERTIFICATIONS

North Carolina Pharmacist License #22676 **2012 – Present**

North Carolina Board of Pharmacy

Michigan Pharmacist License #5302038933 **2014 – Present**

State of Michigan Board of Pharmacy

Advanced Cardiac Life Support **2012 – 2014**

American Heart Association

Immunization Certification **2009 – Present**

American Pharmacists Association

PROFESSIONAL EXPERIENCES

- Infectious Diseases Pharmacokinetic/Pharmacodynamic Fellow** 2013 - 2015
Anti-Infective Research Laboratory
Wayne State University
Detroit, MI
Program Director: Michael J. Rybak, PharmD, MPH
- PGY1 Pharmacy Practice Resident** 2012 – 2013
Moses Cone Hospital
Greensboro, NC
Program Director: Jackie Roh, RPh
- Pharmacy Intern** 2010 – 2012
Central Michigan Community Hospital
Mount Pleasant, MI
Supervisor: James Baxter, RPh
- Pharmacy Intern** 2009 – 2012
Kroger Pharmacy
Howell, MI
Supervisor: Gordon Lange, RPh

PEER REVIEWED PUBLICATIONS

- Xhemali X, **Smith JR**, Kebriaei R, Rice SA, Stamper KC, Compton M, Singh NB, Jahanbakhsh S, Rybak MJ. Evaluation of dalbavancin alone and in combination with beta-lactam antibiotics against resistant phenotypes of *Staphylococcus aureus*. J Antimicrob Chemother. 2018 Sep 27; epub ahead of print.
- Smith JR**, Yim J, Rice S, Stamper K, Kebriaei R, Rybak MJ. Combination of Tedizolid and Daptomycin against Methicillin-Resistant *Staphylococcus aureus* in an *In Vitro* Model of Simulated Endocardial Vegetations. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e101-118.
- Smith JR**, Frens JJ, Snider CB, Claeys KC. Impact of a Pharmacist-Drive Care Package on *Staphylococcus aureus* Bacteremia Management in a Large Community Healthcare Network: A Propensity Score Matched, Quasi-Experimental Study. Diagn Micr Infect Dis. 2018 Jan;90(1):50-54.
- Yim J, **Smith JR**, Singh NB, Rice S, Stamper K, Garcia de la Maria C, Bayer AS, Mishra NN, Miró JM, Tran TT, Arias CA, Sullam P, Rybak MJ. Evaluation of daptomycin combinations with cephalosporins or gentamicin against *Streptococcus mitis* group strains in an *in vitro* model of simulated endocardial vegetations (SEVs). J Antimicrob Chemother. 2017 Aug 1;72(8):2290-2296.
- Stewart CL, Turner MS, Frens JJ, Snider CB, **Smith JR**. Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections. Infect Dis Ther. 2017 Jun;6(2):277-289.
- Yim J, **Smith JR**, Rybak MJ. Role of Combination Antimicrobial Therapy for Vancomycin-Resistant *Enterococcus faecium* Infections: Review of the Current Evidence. Pharmacotherapy. 2017 Mar;37(5):579-592.
- Rolston KV, Wang W, Neshler L, **Smith JR**, Rybak MJ, Prince R. Time-kill determination of the Bactericidal activity of Telavancin and Vancomycin against clinical Methicillin-resistant *Staphylococcus aureus* isolates from Cancer Patients. Diagn Micr Infect Dis. 2017 Apr;87(4):338-342.

Henson KE, Yim J, **Smith JR**, Sakoulas G, Rybak MJ. Beta-lactamase inhibitors enhance the synergy between beta-lactam antibiotics and daptomycin against methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2016 Dec;60(1):e01564-16.

Yim J, **Smith JR**, Barber KE, Hallesy J, Rybak MJ. Evaluation of aztreonam and piperacillin/tazobactam pharmacodynamics with *Pseudomonas aeruginosa*, *Escherichia coli*, and methicillin-resistant *Staphylococcus aureus* (MRSA) in combination with telavancin in an *in-vitro* pharmacokinetic/pharmacodynamic model. *Infect Dis Ther*. 2016 Sep;5(3):367-377.

Smith JR, Arya A, Yim J, Barber KE, Hallesy J, Singh NB, Rybak MJ. Daptomycin in combination with ceftolozane/tazobactam or cefazolin against daptomycin-nonsusceptible *S. aureus* in an *in vitro*, hollow-fiber model. *Antimicrob Agents Chemother*. 2016 Jun;60(7):3970-3975.

Smith JR, Yim J, Raut A, Rybak MJ. Oritavancin combinations with beta-lactams against multidrug-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci. *Antimicrob Agents Chemother*. 2016 Mar;60(4):2352-2358.

Barber KE, **Smith JR**, Raut A, Rybak MJ. Evaluation of Tedizolid against *Staphylococcus aureus* and enterococci with reduced susceptibility to vancomycin, daptomycin, or linezolid. *J Antimicrob Chemother*. 2016 Jan;71(1):152-155.

Smith JR, Roberts K, Rybak MJ. Dalbavancin: A novel lipoglycopeptide antibiotic with extended activity against gram-positive infections. *Infect Dis Ther*. 2015 Sep;4(3):245-258.

Smith JR, Barber KE, Hallesy JA, Raut A, Rybak MJ. Telavancin demonstrates activity against methicillin-resistant *Staphylococcus aureus* with reduced susceptibility to vancomycin, daptomycin, and linezolid via broth microdilution minimum inhibitory concentration and one-compartment pharmacokinetic/pharmacodynamic modeling. *Antimicrob Agents Chemother*. 2015 Sep;59(9):5529-5534.

Barber KE, **Smith JR**, Ireland CE, Boles BR, Rose WE, Rybak MJ. Evaluation of Ceftaroline Alone and in Combination Against Biofilm-producing Methicillin-resistant *Staphylococcus aureus* (MRSA) in an *In Vitro* Pharmacokinetic/Pharmacodynamic Model. *Antimicrob Agents Chemother*. 2015 Aug;59(8):4497-5503.

Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ. Beta-lactam combinations with daptomycin provide synergy against vancomycin-resistant *Enterococcus faecalis* and *Enterococcus faecium* in time kill experiments. *J Antimicrob Chemother*. 2015 June;70(6):1738-1743.

Smith JR, Barber KE, Raut A, Rybak MJ. Beta-lactams enhance daptomycin activity demonstrate synergy against vancomycin-resistant *Enterococcus faecalis* and *Enterococcus faecium* in *in vitro* pharmacodynamic/pharmacokinetic models. *Antimicrob Agents Chemother*. 2015 May;59(5):2842-2848.

Claeys KC, **Smith JR**, Casapao AM, Mynatt RP, Avery L, Shroff A, Davis SL, Rybak MJ. Combination Daptomycin and Trimethoprim/Sulfamethoxazole on Clinical Outcomes in Methicillin-Resistant *S. aureus* Infections. *Antimicrob Agents Chemother*. 2015 Apr;59(4):1969-1976.

Smith JR, Barber KE, Claeys KC, Rybak MJ. High-dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It. *Curr Infect Dis Rep*. 2014 Oct;16(10):429.

PEER REVIEWED PUBLICATIONS IN PROGRESS

Trinh TD, **Smith JR**, Rybak MJ. Intravenous Fosfomycin for Multidrug-Resistant Bacteria: May the Force Be With You.

SCIENTIFIC POSTERS

Smith JR, Frens JJ, Snider C, Claeys KC. Effects of a *Staphylococcus aureus* Bacteremia Care Package Intervention on Patient Care in a Community Teaching Hospital: A Propensity-Score Matched Comparison. Infectious Diseases Society of America IDWeek. Poster. New Orleans, LA. October 2016.

Yim J, **Smith JR**, Singh N, Hallesy JA, Garcia de la Maria C, Bayer AS, Mishra NN, Miro JM, Arias CA, Tran TT, Sullam P, Rybak MJ. Combination of Daptomycin (DAP) and Ceftaroline (CPT) or Gentamicin (GEN) Against *Streptococcus mitis* in an *In Vitro* Model of Simulated Endocardial Vegetations (SEVs). American Society for Microbiology Microbe Annual Meeting. Poster. Boston, MA. June 2016.

Yim J, **Smith JR**, Hallesy JA, Singh N, Arias CA, Rybak MJ. Synergy Between β -lactams (BLs) and Daptomycin (DAP) Against Vancomycin-resistant Enterococci (VRE) in an *In Vitro* Pharmacokinetic/Pharmacodynamic (PK/PD) Biofilm Model: Does This Apply to All VRE? American Society for Microbiology Microbe Annual Meeting. Poster. Boston, MA. June 2016.

Henson KR, Yim J, **Smith JR**, Sakoulas G, Rybak MJ. Evaluation of Daptomycin (DAP) Combined with β -lactams (BL) and β -lactamase Inhibitors (BLI) against Methicillin-Resistant *Staphylococcus aureus* (MRSA). American Society for Microbiology Microbe Annual Meeting. Poster. Boston, MA. June 2016.

Yim J, **Smith JR**, Barber KE, Raut A, Singh N, Kaye KS, Rybak MJ. Evaluation of colistin (COL) and meropenem (MEM) against clinical isolates of extensively drug-resistant (XDR) gram-negative bacilli. Making a Difference in Infectious Diseases Annual Meeting. Poster. Orlando, FL. May 2016.

Smith JR, Yim J, Hallesy JA, Mishra NN, Garcia-de-la-Maria C, Miro JM, Arias CA, Sullam P, Bayer AS, Rybak MJ. Ceftaroline (CPT) and Daptomycin (DAP) Are Synergistic Against *Streptococcus mitis* in an *In Vitro* Model of Simulated Endocardial Vegetations (SEVs). Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. San Diego, CA. September 2015.

Smith JR, Raut A, Yim J, Rybak MJ. Beta-lactams Enhance Oritavancin (ORI) Activity Against Methicillin-resistant *Staphylococcus aureus* (MRSA) with Reduced Susceptibility to Daptomycin and Vancomycin-resistant enterococci (VRE). Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. San Diego, CA. September 2015.

Smith JR, Yim J, Hallesy JA, Arias CA, Rybak MJ. β -lactam Antibiotics Enhance Daptomycin Activity Against Vancomycin-resistant enterococci in an *In Vitro* Biofilm Model. Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. San Diego, CA. September 2015.

Levine MT, **Smith JR**, Yim J, Levine DP, Rybak MJ. An Evaluation of Synergistic Antibiotic Combinations to Treat Persistent enterococcal Bacteremia. Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. San Diego, CA. September 2015.

Yim J, **Smith JR**, Barber KE, Raut A, Singh N, Kaye KS, Rybak MJ. Evaluation of Colistin (COL) and Meropenem (MEM) Against Clinical Isolates of Extensively Drug-resistant (XDR) Gram-negative Bacilli. Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. San Diego, CA. September 2015.

Yim J, **Smith JR**, Barber KE, Hallesy JA, Rybak MJ. Evaluation of Aztreonam (ATM) and Piperacillin/tazobactam (PIP-TAZ) Pharmacodynamics with *Pseudomonas aeruginosa*, *Escherichia coli*, and Methicillin-resistant *Staphylococcus aureus* (MRSA) in Combination with Telavancin (TLV) in an *in-vitro* Pharmacokinetic/Pharmacodynamic (PK/PD) Model. Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. San Diego, CA. September 2015.

Yim J, **Smith JR**, Singh N, Raut A, Rybak MJ. Evaluation of the Activity of Telavancin (TLV), Vancomycin (VAN), Teicoplanin (TEI), and Daptomycin (DAP) Combinations against Biofilm-producing Methicillin-resistant *Staphylococcus aureus* (MRSA). Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. San Diego, CA. September 2015.

Henson KR, Levine MT, **Smith JR**, Yim J, Raut A, Rybak MJ. Evaluation of Daptomycin Combined with Beta-Lactams Against Daptomycin-Nonsusceptible *Staphylococcus aureus* and Vancomycin-Resistant enterococci. Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. San Diego, CA. September 2015.

Smith JR, Yim J, Raut A, Rybak MJ. The combination of colistin, meropenem, and daptomycin provides synergistic activity against *Acinetobacter baumannii*. European Congress of Clinical Microbiology and Infectious Diseases. Poster. Copenhagen, Denmark. April 2015.

Smith JR, Yim J, Raut A, Rybak MJ. Cephalosporin combinations with telavancin provide synergy against methicillin-resistant *Staphylococcus aureus* (MRSA). European Congress of Clinical Microbiology and Infectious Diseases. Poster. Copenhagen, Denmark. April 2015.

Smith JR, Barber KE, Sakoulas G, Rybak MJ. Beta-lactam Combinations with Daptomycin (DAP) Provide Synergy against Vancomycin-Resistant *Enterococcus faecalis* and *Enterococcus faecium*. Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. Washington, D.C. September 2014.

Smith JR, Barber KE, Raut A, Rybak MJ. Minimum Inhibitory Concentrations (MIC) of Telavancin (TLV) against Methicillin-Resistant *Staphylococcus aureus* (MRSA) with Reduced Susceptibility to Daptomycin (DAP), Vancomycin (VAN), or Linezolid (LZD). Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. Washington, D.C. September 2014.

Frens JJ, **Smith JR**, Snider CB. Impact of an Antimicrobial Stewardship Team on the Outcomes of Patients with *Staphylococcus aureus* Bacteremia in a Community Hospital System. Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. Washington, D.C. September 2014.

Barber KE, **Smith JR**, Ireland CE, Rose WE, Rybak MJ. Evaluation of Ceftaroline against Biofilm-Producing Methicillin-Resistant *Staphylococcus aureus* in an *In Vitro* Pharmacokinetic/Pharmacodynamic Model. Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster. Washington, D.C. September 2014.

Smith JR, Barber KE, Sakoulas G, Rybak MJ. Time Kill Evaluation of Daptomycin Combinations against Clinical Isolates of *Staphylococcus aureus* and *Enterococcus faecalis* and *Enterococcus faecium*. Making a Difference in Infectious Diseases Annual Meeting. Poster. Orlando, FL. May 2014.

Smith JR, Barber KE, Rybak MJ. Beta-lactam combinations with daptomycin provide synergy against methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci. European Congress of Clinical Microbiology and Infectious Diseases. ePoster. Barcelona, Spain. May 2014.

Smith JR, Frens J. Management of *Staphylococcus aureus* bacteremia in the acute care setting: Effect of an antimicrobial stewardship team on appropriate antibiotic therapy and outcomes. Making a Difference in Infectious Diseases Annual Meeting. Poster. Orlando, FL. May 2013.

BOOK CHAPTERS

Smith JR, Claeys KC, Zasowski EJ, Yim J, Rybak MJ. Daptomycin nonsusceptibility. Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, Volume 1, 2nd Edition. Springer; 2017.

GRANTSMANSHIP

Smith JR, Frens JJ. Optimizing Transitions of Care Antimicrobial Prescribing at a Community Teaching Hospital. Making a Difference in Infectious Diseases. (\$30,000; pending) **May 2019**

Smith JR, Frens JJ, Snider CB. Curbing the Use of Unnecessary Screening and Antibiotic Use in the Emergency Department: An Emphasis on Bacteriuria. Making a Difference in Infectious Diseases. (\$30,000; not funded) **May 2017**

Smith JR. Impact of a Pharmacist-Driven Acute Bacterial Skin and Skin Structure Infection Management Package. American Society of Health Systems Pharmacists. (\$20,000; not funded) **October 2016**

Smith JR, Frens JJ, Snider C, Turner M. Evaluation of a pharmacist-driven antimicrobial stewardship intervention targeting therapy of healthcare-associated pneumonia (HCAP) and HCAP complicated by the presence of urinary tract pathogens. American Society of Health Systems Pharmacists. (\$75,000; not funded) **October 2015**

Rybak MJ, Arias CA, **Smith JR**. R01: Dose optimization of daptomycin alone and in combination with beta-lactams against *Enterococcus faecium* with defined genetic mutations. National Institute of Allergies and Infectious Disease R-01. (\$1,935,719; funded) **January 2015**

Yim J, **Smith JR**, Rybak MJ. Evaluation of telavancin alone and combined with ceftaroline or rifampin against methicillin-resistant *Staphylococcus aureus* (MRSA) in an *in vitro* PK/PD model of bacterial biofilm. Theravance, Inc. (\$94,768; funded) **January 2015**

Smith JR, Yim J, Rybak MJ. Evaluation of the Activity of Oritavancin Alone and in Combination with Beta-lactams in Combination Minimum Inhibitory Concentration (MIC) Testing and Time Kill Assays Against Resistant Phenotypes of *Staphylococcus aureus* and *Enterococcus spp.* The Medicines Company, Inc. (\$53,211; funded) **December 2014**

Smith JR, Yim J, Rybak MJ. Evaluation of Telavancin compared to Daptomycin and Vancomycin in an *In Vitro* Pharmacokinetic Model against Methicillin-Resistant *Staphylococcus aureus* (MRSA) Intermediately Susceptible to Vancomycin (VISA), Nonsusceptible to Daptomycin (DNS), and DNS VISA. Theravance, Inc. (\$129,083; not funded) **November 2014**

<p>Smith JR, Rybak MJ. Equipment Grant Request for digital fluorescent microscope and computerized pneumatic pressurized microfluidic channel plate system for biofilm characterization. Wayne State University Competitive Equipment Grant (\$50,000; funded)</p>	<p>November 2014</p>
<p>Smith JR, Yim J, Zasowski E, Rybak MJ. Activity of a Novel Combination of Amikacin and Fosfomycin against <i>Pseudomonas aeruginosa</i> in a Hollow-Fiber Pharmacokinetic/Pharmacodynamic Model. Cardeas Pharmaceuticals, Inc. (\$86,012; not funded)</p>	<p>August 2014</p>
<p>Smith JR, Yim J, Zasowski E, Rybak MJ. Evaluation of de-escalation from a combination regimen of daptomycin and tedizolid to either agent alone against <i>Staphylococcus aureus</i> in a pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Cubist Pharmaceuticals, Inc. (\$159,530; funded)</p>	<p>August 2014</p>
<p>Smith JR, Arya A, Rybak MJ. Activity of Daptomycin Alone or in Combination with Ceftolozane in a Hollow-Fiber Pharmacokinetic/Pharmacodynamic Model. Cubist Pharmaceuticals, Inc. (\$19,375.00; funded)</p>	<p>July 2014</p>
<p>Smith JR, Barber KE, Raut A, Rybak MJ. Comparison of a Novel Rapid Diagnostic hVISA Screening Method to Population Analysis Profile-Area Under the Curve (PAP-AUC) and Etest GRD. Accelerate Diagnostics, Inc. (\$61,744.07; not funded)</p>	<p>April 2014</p>
<p>Smith JR, Barber KE, McRoberts JP, Ireland CE, Rybak MJ. Minimum inhibitory concentrations (MIC) of telavancin against MRSA with reduced susceptibility to daptomycin, vancomycin, or linezolid. Theravance, Inc. (\$77,614.60; funded)</p>	<p>March 2014</p>
<p>Barber KE, Smith JR, McRoberts JP, Ireland CE, Rybak MJ. Evaluation of Aztreonam and Piperacillin/tazobactam Pharmacodynamics with <i>Pseudomonas aeruginosa</i> and methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in Combination with Telavancin in an <i>in vitro</i> Pharmacodynamic model. Theravance, Inc. (\$77,786.83; funded)</p>	<p>March 2014</p>
<p>Smith JR, Barber KE, Rybak MJ. Evaluation of ceftaroline (CPT), daptomycin (DAP), or CPT plus DAP against DAP susceptible and DAP nonsusceptible (DNS) <i>Enterococcus faecium</i> in an <i>in vitro</i> model of simulated endocardial vegetations. Forest Laboratories. (\$80,000.00; not funded)</p>	<p>January 2014</p>
<p>Smith JR, Barber KE, Rybak MJ. Evaluation of ceftaroline alone or in combination with glycopeptides and lipopeptides against two <i>Staphylococcus aureus</i> isogenic strain pairs in a pharmacokinetic/pharmacodynamic model.</p>	<p>September 2013</p>

Forest Laboratories. (\$83,440.37; not funded)

PRECEPTING EXPERIENCE

Moses Cone PGY-2 Infectious Diseases Residency

2017 – Present

Rotation preceptor

Supervise PGY-2 resident in a month-long academic residency and provide insight and statistical analysis for resident projects

TEACHING EXPERIENCE

PCS 7840: Pharmacotherapy II

Jan-Apr 2019

Course coordinator

Fred Wilson School of Pharmacy, High Point University
High Point, NC

PCS 7840: Pharmacotherapy II

Jan-Apr 2019

Course coordinator

Fred Wilson School of Pharmacy, High Point University
High Point, NC

PBS 7330: Immunology

Jan-Apr 2019

Course co-coordinator and lecturer

Fred Wilson School of Pharmacy, High Point University
High Point, NC

PCS 7520: Health Care Systems I

Sep-Dec 2018

Course coordinator

Fred Wilson School of Pharmacy, High Point University
High Point, NC

PCS 7010: Introduction to Pharmacy Practice Laboratory

Sep-Dec 2018

Faculty member responsible for a portion of the immunization certificate course

Fred Wilson School of Pharmacy, High Point University
High Point, NC

PCS 7000: Introduction to Pharmacy Practice

Sep-Dec 2018

Faculty lecturer for the drug information portion of the course

Fred Wilson School of Pharmacy, High Point University
High Point, NC

PCS 7840: Pharmacotherapy II

Jan-Apr 2018

Course coordinator

Fred Wilson School of Pharmacy, High Point University
High Point, NC

PCS 7800: Clinical Skills Lab IV

Jan-Apr 2018

Faculty member responsible for a portion of the laboratory materials

Fred Wilson School of Pharmacy, High Point University
High Point, NC

<p>PBS 7330: Immunology Course co-coordinator and lecturer Fred Wilson School of Pharmacy, High Point University High Point, NC</p>	<p>Jan-Apr 2018</p>
<p>PBS 7340: Pharmacokinetics Course co-coordinator and lecturer Fred Wilson School of Pharmacy, High Point University High Point, NC</p>	<p>Jan-Apr 2018</p>
<p>PCS 7520: Health Care Systems I Course coordinator Fred Wilson School of Pharmacy, High Point University High Point, NC</p>	<p>Sep-Dec 2017</p>
<p>PCS 7010: Introduction to Pharmacy Practice Laboratory Faculty member responsible for a portion of the immunization certificate course Fred Wilson School of Pharmacy, High Point University High Point, NC</p>	<p>Sep-Dec 2017</p>
<p>PCS 7000: Introduction to Pharmacy Practice Faculty lecturer for the drug information portion of the course Fred Wilson School of Pharmacy, High Point University High Point, NC</p>	<p>Sep-Dec 2017</p>
<p>PBS 7330: Immunology Course co-coordinator and lecturer Fred Wilson School of Pharmacy, High Point University High Point, NC</p>	<p>Jan-Apr 2017</p>
<p>PBS 7340: Pharmacokinetics Course co-coordinator and lecturer Fred Wilson School of Pharmacy, High Point University High Point, NC</p>	<p>Jan-Apr 2017</p>
<p>FYS 1000: America's Drug Culture Course coordinator Fred Wilson School of Pharmacy, High Point University High Point, NC</p>	<p>Sep-Dec 2016</p>
<p>PCS 7010: Introduction to Pharmacy Practice Laboratory Faculty member responsible for a portion of the immunization certificate course Fred Wilson School of Pharmacy, High Point University High Point, NC</p>	<p>Sep-Dec 2016</p>
<p>PCS 7000: Introduction to Pharmacy Practice</p>	<p>Sep-Dec 2016</p>

Faculty lecturer for the drug information portion of the course
Fred Wilson School of Pharmacy, High Point University
High Point, NC

PHA 4210: Infectious Diseases Pharmacotherapy Introduction to infectious diseases lecture and flipped class case discussions Wayne State University College of Pharmacy Detroit, MI	February 2014
Infectious Diseases APPE Co-preceptor for a fourth year PharmD candidate Wayne State University College of Pharmacy Detroit, MI	September 2014
Infectious Diseases Directed Study Lead investigator for student research projects for three PharmD candidates Wayne State University College of Pharmacy Detroit, MI	May-September 2014
Infectious Diseases APPE Co-preceptor for a fourth year PharmD candidate Wayne State University College of Pharmacy Detroit, MI	February 2014
PHA 4210: Infectious Diseases Pharmacotherapy Bone and Joint Infections Lecture Wayne State University College of Pharmacy	February 2014
Internal Medicine APPE Co-preceptor for a fourth year PharmD candidate Campbell University College of Pharmacy Greensboro, NC	May 2013
Kinesiology Teaching Series OTC Antifungal and Antiviral Therapy Lecture University of North Carolina at Greensboro Greensboro, NC	April 2013
Cardiology APPE Co-preceptor for a fourth year PharmD candidate University of North Carolina College of Pharmacy Greensboro, NC	November 2012
Infectious Diseases APPE Co-preceptor for a fourth year PharmD candidate University of North Carolina College of Pharmacy Greensboro, NC	October 2012
Nurse Practitioner Teaching Series Depression, Anxiety, and Bipolar Disorder Lecture University of North Carolina at Greensboro	October 2012

Greensboro, NC

Nurse Practitioner Teaching Series

September 2012

Pneumonia, Upper Respiratory Tract Infections, and Steroids
University of North Carolina at Greensboro
Greensboro, NC

PRESENTATIONS

Biofilm: *In Vitro* and Clinical Implications

December 2017

University of Maryland College of Pharmacy
Baltimore, MD

Translating *In Vitro* Research into Clinical Practice

August 2017

Moses Cone Hospital
Greensboro, NC

Gram-Positive Infections: *In Vitro* Research and Clinical Implications

April 2016

Faculty Seminar Presentation
Fred Wilson School of Pharmacy, High Point University
High Point, NC

Gram-Positive Infections: Problems and Potential Solutions

November 2015

Anti-Infective Workshop Invited Lecture
Greensboro, NC

Combatting Enterococcal Biofilm with Beta-lactam and Daptomycin Combinations

May 2015

Fellowship Forum Platform Presentation
Brainerd, Minnesota

Preventing and Overcoming Resistance in Enterococci

March 2015

University of Kentucky Invited Lecture
Lexington, KY

Evaluation of Beta-Lactam Combinations with Daptomycin against *Enterococcus spp.*

April 2014

Fellowship Forum Platform Presentation
Captiva Island, FL

Management of *Staphylococcus aureus* bacteremia in the acute care setting: Effect of an antimicrobial stewardship team on appropriate antibiotic therapy and outcomes

April 2013

Southeastern Residency Conference
Athens, GA

PROFESSIONAL SERVICE

Internet/Social Media Committee

November 2017 – Present

Voting member
Society of Infectious Diseases Pharmacists
National Committee

Co-Curriculum Committee Chair Fred Wilson School of Pharmacy, High Point University High Point, NC	June 2017 – Present
Curriculum Committee Voting member Fred Wilson School of Pharmacy, High Point University High Point, NC	June 2017 – Present
Institutional Animal Care and Use Committee Voting member High Point University High Point, NC	August 2015 – Present
Assessment Committee Voting member Fred Wilson School of Pharmacy, High Point University High Point, NC	August 2015 – August 2018
Academic Standards Committee Voting member Fred Wilson School of Pharmacy, High Point University High Point, NC	August 2016 – August 2017

AWARDS AND HONORS

Young Professional of the Year (Nominated) High Point Chamber of Commerce	February 2017
Resident/Fellow Travel Grant Making a Difference in Infectious Diseases Annual Conference	May 2015
Young Scientist Travel Grant European Congress of Clinical Microbiology and Infectious Diseases	April 2015
Infectious Disease Fellows Travel Grant Interscience Conference on Antimicrobial Agents and Chemotherapy	September 2014
Young Scientist Travel Grant European Congress of Clinical Microbiology and Infectious Diseases	May 2014
Resident/Fellow Travel Grant Making a Difference in Infectious Diseases Annual Conference	May 2014
Resident/Fellow Travel Grant Making a Difference in Infectious Diseases Annual Conference	May 2013
Dean’s Scholarship University of Michigan College of Pharmacy Ann Arbor, MI	2010 – 2012

Mid-Michigan Health Bailey Foundation Scholarship 2008 – 2012
University of Michigan College of Pharmacy
Ann Arbor, MI

PROFESSIONAL MEMBERSHIPS

American Pharmacists Association	2016 – Present
Infectious Diseases Society of America	2013 – Present
American Society for Microbiology (ASM)	2013 – Present
European Society of Clinical Microbiology and Infectious Diseases	2013 – Present
Society of Infectious Diseases Pharmacists (SIDP)	2013 – Present
American College of Clinical Pharmacy (ACCP)	2012 – 2013
American Society of Health System Pharmacists (ASHP)	2008 – 2013

REFERENCES

Mary Jayne Kennedy
Department Chair
Professor and chair
Fred Wilson School of Pharmacy
High Point University
One University Parkway
High Point, NC 27265
mkenned2@highpoint.edu
(336) 841-9714

Michael J. Rybak, PharmD, Ph.D., MPH
Fellowship director and mentor
Professor
Eugene Applebaum College of Pharmacy and Health Sciences
Wayne State University
259 Mack Avenue
Detroit, MI 48201
m.rybak@wayne.edu
(313) 577-4376

Susan L. Davis, PharmD
Mentor
Associate clinical professor
Eugene Applebaum College of Pharmacy and Health Sciences
Wayne State University
259 Mack Avenue
Detroit, MI 48201
sldavis@wayne.edu

(313) 577-5451